For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Combined Sales of 27 JPMA Member Firms Up 4.9% to \5,526 Bil.
June 3, 2002
- AstraZeneca, Shionogi to Comarket New Statin Crestor
June 3, 2002
- Yamanouchi: Sales Up 5.1% Thanks to Harnal, Lipitor
June 3, 2002
- Iressa to Be Approved in Japan before US, Europe
June 3, 2002
- Korosho to Issue Notification to Promote Use of Generics
May 27, 2002
- White Paper Calls for Improved Environment for Small, Medium-sized Firms
May 27, 2002
- Kenporen Calls for Steady Healthcare Reform
May 27, 2002
- Shiseido: Domestic Sales Down for Both Cosmetics, Toiletries
May 27, 2002
- Pharmacies Employ Largest Number of Pharma Graduates
May 27, 2002
- Household Healthcare Costs Up 3.2%
May 27, 2002
- BMS: 1st Qtr Sales Down 7.0% to US$4.3 Bil.
May 27, 2002
- 12-hour Night Shift Work for Nurses Increasing: JNA Survey
May 27, 2002
- Eiken: Sales Up 2.5% to \21.3 Bil., Net Profits Up 44.4% to \1.2 Bil.
May 27, 2002
- Neoral Reduces Kidney Rejection Rates: MO2ART Study
May 27, 2002
- Worker Consultation Service Receives 5,398 Calls: LWC Survey
May 27, 2002
- Kainos: Automatic ELISA System for Microplates
May 27, 2002
- Will the FY2002 Medical Fee Revision Promote Use of Generics? - Strategies of Major GE Makers - （1）
May 27, 2002
- Improvement of Nurse Training Recommended
May 27, 2002
- WEBSITE NEWS
May 27, 2002
- Will the FY2002 Medical Fee Revision Promote Use of Generics? - Strategies of Major GE Makers - （2）
May 27, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…